Brussels - Brussels Delayed Price. Currency in EUR
70.26-1.58 (-2.20%)
At close: 11:35 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close71.84
Bid64.00 x 203800
Ask66.00 x 10000
Day's Range70.23 - 71.73
52wk Range61.60 - 86.05
1y Target EstN/A
Market Cap13.23B
P/E Ratio (ttm)20.37
Avg Vol (3m)238,557
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • PR Newswire5 hours ago

    Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab

    THOUSAND OAKS, Calif. and BRUSSELS, Sept. 26, 2016 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for romosozumab, an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. "We believe romosozumab could serve as an important therapeutic option for osteoporosis patients with an increased risk of fracture," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. The BLA, submitted on July 19, 2016, is based on data from the pivotal Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME) in approximately 7,200 patients.

  • PR Newswire7 days ago

    UCB Opens Solution Accelerator at Georgia Tech Technology Square

    ATLANTA, Sept. 20, 2016 /PRNewswire/ -- UCB announced today the opening of its UCB Solution Accelerator – a unique environment designed to drive collaboration between UCB and the Georgia Tech community to develop solutions that will positively impact the lives of those living with severe diseases. The 2,500-square foot innovation center will be located in midtown Atlanta's Centergy Building at Technology Square, part of Georgia Tech's innovation neighborhood. With its North America Headquarters in Smyrna, GA, UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to treat severe diseases of the immune and central nervous system.

  • PR Newswire8 days ago

    Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis

    THOUSAND OAKS, Calif. and BRUSSELS, Sept. 18, 2016 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced findings from the FRAME study showing that the investigational agent romosozumab significantly reduced the incidence of new vertebral fractures in postmenopausal women with osteoporosis through 12 and 24 months, meeting the study's co-primary endpoints. Of interest, the data showed that by six months, new vertebral fractures occurred in 14 romosozumab and 26 placebo patients, and between six to 12 months, fractures occurred in two additional romosozumab patients versus 33 additional placebo patients.